0001362718 – Page 10 – China Stock Advice

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Second Quarter Fiscal Year 2014 Financial

[TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31,] [Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator I will now turn the presentation over to James Tong, CFO of the Company. Dr. Tong: Second Quarter of Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K Current Report February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction Identification No.) (IRS Employer of incorporation) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By info| 2016-03-19T15:55:05+00:00 February 21st, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2014-02-21, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: (Original Filing)

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By info| 2016-03-19T16:02:01+00:00 February 14th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 2014-02-14, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: for a reporting persons initial filing on this

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By info| 2016-03-19T16:04:11+00:00 February 14th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2014-02-14, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G/A: (Original Filing)

[CUSIP No. 88630M104 1. Names of reporting persons. I.R.S. Identification Nos. of above persons (entities only). 11-3694008 2. Check the appropriate box if a member of a group (see instructions) ¨ x (a) 3. SEC use only 4. Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: 5. Sole voting power 0 6.]

By info| 2016-03-19T15:56:12+00:00 February 14th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 2014-02-14, 2834, PHARMACEUTICAL PREPARATIONS, SC_13G.A, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1213ex32i_tianyinphar.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q1213ex32ii_tianyinphar.htm CERTIFICATION]

By info| 2016-03-19T15:59:49+00:00 February 14th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: 0001362718, 10-Q, 2014-02-14, 2834, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman EX-32.1 4 f10q1213ex32i_tianyinphar.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director EX-32.2 5 f10q1213ex32ii_tianyinphar.htm CERTIFICATION]

By info| 2016-03-19T16:00:54+00:00 February 14th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 10-Q, 2014-02-14, 2834, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports First Quarter Fiscal Year 2014 Financial

[TPI Reports First Quarter Fiscal Year 2014 Financial Results November 15, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter fiscal year 2014. First Quarter Fiscal Year 2014 Ended September 30, 2013 Financial Highlights:] [Tianyin Pharmaceutical Inc. First Quarter Fiscal Year 2014 Financial Results Conference Call November 15, 2013 Operator. I will now turn the presentation over to James Tong. Please go ahead, Mr. Tong. James Tong Below are the financial highlights for the first quarter of fiscal year 2014 ended September 30, 2013: Revenue totaled $14.8 million, compared with $16.0 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By info| 2016-03-27T17:49:02+00:00 November 20th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: 0001362718, 2013-11-20, 2834, 8-K, PHARMACEUTICAL PREPARATIONS, TPI|0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 4, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]